Phase 1b/2 trial expected to initiate 1Q 2019

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Phase 1b/2 trial expected to initiate 1Q 2019

posted on Mar 06, 2019 10:45AM

Tick tock guys. What's going on here? 25 days left in Q1 2019. Nothing up on ClinicalTrials.gov yet.

News released Nov 20, 2018: Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

"Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019"

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply